BB Biotech AG
Deutsche BörseTotal Valuation
BB Biotech AG carries a market capitalization of 2.99B, placing it among publicly traded companies globally. Its enterprise value stands at 1.64B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 2.99B |
| Enterprise Value | 1.64B |
Share Statistics
BB Biotech AG currently has 54.63M shares outstanding.
| Shares Outstanding | 54.63M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
BB Biotech AG trades at a trailing price-to-earnings ratio of 31.02. The price-to-sales ratio is -3.90, and the price-to-book ratio stands at 0.87.
| PE Ratio | 31.02 |
| PS Ratio | -3.90 |
| PB Ratio | 0.87 |
| P/TBV Ratio | 0.89 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
| EV / Sales | 17.00 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Efficiency
| Return on Equity (ROE) | -20.37 |
| Return on Assets (ROA) | -19.26 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 46,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
BB Biotech AG's stock has gained approximately 69.11076% over the past 52 weeks. The 50-day moving average sits at 33.40, while the 200-day moving average is 33.40.
| Beta (5Y) | N/A |
| 52-Week Price Change | 69.11076% |
| 50-Day Moving Average | 33.40 |
| 200-Day Moving Average | 33.40 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, BB Biotech AG generated -421.02M in revenue and converted that into -438.69M in net income, yielding earnings per share of -8.01.
| Revenue | -421.02M |
| Gross Profit | N/A |
| Operating Income | N/A |
| Pretax Income | -438.64M |
| Net Income | -438.69M |
| EBITDA | N/A |
| EBIT | N/A |
| Earnings Per Share (EPS) | -8.01 |
Balance Sheet
| Cash & Cash Equivalents | 2.16M |
| Total Debt | N/A |
| Net Debt | -2.16M |
| Equity (Book Value) | 1.88B |
| Book Value Per Share | 34.41 |
| Working Capital | N/A |
Margins
BB Biotech AG operates with a gross margin of 100.00, reflecting its pricing power and cost economics.
| Gross Margin | 100.00 |
| Operating Margin | N/A |
| Pretax Margin | 104.19 |
| Profit Margin | 104.20 |
| EBITDA Margin | N/A |
Dividends & Yields
The company's payout ratio of -22.45 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 1.80 |
| Dividend Yield | N/A |
| Payout Ratio | -22.45 |
| Shareholder Yield | 26.03 |
| FCF Yield | N/A |
Stock Splits
BB Biotech AG's most recent stock split took place on March 29, 2016 with a 1:5 split ratio.
| Last Split Date | 3/29/2016 |
| Split Ratio | 1:5 |
Scores
BB Biotech AG posts an Altman Z-Score of 405.94, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 405.94 |